CFLAR and hepatocellular carcinoma: Therefore, several studies have focused on attenuating the inhibition of cellular apoptosis through FLIP downregulation, which increases the sensitivity to TRAIL [11, 12], suggesting its promising therapeutic potential in HCC treatment.